Figure 5.

Reduction from baseline in the levels of glycoprotein acetylation (GlycA) following type I IFN pathway inhibition in patients with SLE. A, GlycA levels measured at baseline by nuclear magnetic resonance spectroscopy in healthy donors or IFNGS test–high patients with SLE. The AUC is indicated, along with P values calculated by Mann-Whitney U test. B, GlycA levels measured on day 1 and day 365 in IFNGS test–high GlycA-high patients with SLE who were treated with 300 mg of anifrolumab or placebo. GlycA-high was defined as levels ≥2 SD above the mean level in healthy donors (mean 500 μM). P values were calculated using Wilcoxon’s signed rank test. Values are shown as box plots. Each box represents the 25th and 75th percentiles, lines inside the boxes represent the median, and whiskers represent the ranges. Symbols represent individual subjects. NS = not significant (see Figure 1 for other definitions).